X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Pandion's lead candidate, PT101, is an engineered IL-2 mutein fused to a protein backbone designed to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of ulcerative colitis and other autoimmune diseases.
Lead Product(s): PT101
Therapeutic Area: Gastroenterology Product Name: PT101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $1,850.0 million Upfront Cash: $1,850.0 million
Deal Type: Acquisition April 01, 2021
Details:
Under the terms of the agreement, Pandion will utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the research cell banks (RCBs) necessary to advance PT627 to human trials.
Lead Product(s): PT627
Therapeutic Area: Immunology Product Name: PT627
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: KBI Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 16, 2021
Details:
Pandion's lead candidate, PT101, is an engineered IL-2 mutein fused to a protein backbone designed to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of ulcerative colitis and other autoimmune diseases.
Lead Product(s): PT101
Therapeutic Area: Gastroenterology Product Name: PT101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $1,850.0 million Upfront Cash: $1,850.0 million
Deal Type: Acquisition February 25, 2021
Details:
The research, done in collaboration with St Vincent’s Institute of Medical Research in Australia and funded by JDRF and the JDRF T1D Fund, showed that PT001 treatment delayed the onset of hyperglycemia in a mouse model of Type 1 diabetes.
Lead Product(s): Glycopyrronium Bromide
Therapeutic Area: Immunology Product Name: PT001
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
Pandion utilizes its TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform to create antibody-based candidates that target known control nodes in the immune system.
Lead Product(s): Glycopyrronium Bromide
Therapeutic Area: Immunology Product Name: PT001
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
Funds will be used in company's lead asset, PT101, a combination of an interleukin-2 mutein effector module with a protein backbone, designed to selectively expand regulatory T cells systemically without activating proinflammatory cells.
Lead Product(s): PT101
Therapeutic Area: Gastroenterology Product Name: PT101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 29, 2020
Details:
Patent protects foundational intellectual property and pioneering work on Pandion’s therapeutic autoimmune regulatory protein (TALON) drug design platform.
Lead Product(s): PT101
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Details:
Proceeds to support advancement of pipeline of modular proteins and bifunctional antibodies for autoimmune diseases, including lead clinical-stage IL?2 mutein program.
Lead Product(s): PT101
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Access Biotechnology
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 01, 2020
Details:
Trial to evaluate safety and tolerability of PT101, as well as expansion of regulatory T cells.
Lead Product(s): PT101
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2020
Details:
Under the agreement, Pandion will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse®, OmniChicken® and OmniClic™.
Lead Product(s): Antibodies
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Ligand Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
